Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05789082 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
A Phase 1 study of Non-Small Cell Lung Cancer, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 320
- Enrollment target
- 20
- Study locations
NCT05789082 is a Phase 1 study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 320 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (51% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT05789082, a Phase 1 study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 320 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and activity of single-agent divarasib or combined with other anti-cancer therapies in participants with previously untreated, advanced or metastatic non-small cell lung cancer (NSCLC).
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Pemetrexed
- DRUG Divarasib
Study Locations (20)
California
- City of Hope National Medical Center - Duarte
- City of Hope - Seacliff - Huntington Beach
- City of Hope at Irvine Lennar - Irvine
- UCSD Moores Cancer Center - La Jolla
- City of Hope - Long Beach Elm - Long Beach
New York
- NYU Langone Hospital - Long Island - Mineola
- NYU Cancer Center - New York
- Mount SInai Medical Center - New York
- Montefiore Medical Center - Montefiore Medical Park - The Bronx
Florida
- Florida Cancer Specialists - SOUTH - SCRI - PPDS - Fort Myers
- Florida Cancer Specialists - NORTH - SCRI - PPDS - St. Petersburg
- Florida Cancer Specialists - EAST - SCRI - PPDS - West Palm Beach
Other
- Hospital Britanico - Buenos Aires
- Clinica Adventista Belgrano - Ciudad Autonoma Buenos Aires
- Centro Oncologico Riojano Integral (CORI) - La Rioja
Virginia
- Oncology & Hematology Associates of Southwest Virginia, Inc - Blacksburg
- Virginia Oncology Associates - Norfolk
Connecticut
- Yale Cancer Center - New Haven
Texas
- MD Anderson Cancer Center - Houston
New South Wales
- Concord Repatriation General Hospital - Concord
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2023-06-20 |
| Est. Completion | 2032-01-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05789082
The ClinicalTrials.gov registry entry for NCT05789082 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 320 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (51% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT05789082 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, New York, Florida.
Frequently Asked Questions
What is clinical trial NCT05789082 about?
NCT05789082 is a clinical study titled "A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation". The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and activity of single-agent divarasib or combined with other anti-cancer therapies in participants with previously untreated, advanced or metastatic non-small cell lung cancer (NSCLC).
What is the current status of trial NCT05789082?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 320 participants. The study started on 2023-06-20. Estimated completion is 2032-01-29.
What conditions does trial NCT05789082 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT05789082?
The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Cisplatin (DRUG), Pemetrexed (DRUG), Divarasib (DRUG).
Who is sponsoring clinical trial NCT05789082?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05789082 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.